INCY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Incyte Corp is not a strong buy at the moment for a beginner investor with a long-term focus. While the company demonstrates strong financial growth and has promising developments in its pipeline, the lack of immediate catalysts, neutral trading sentiment, and concerns about the Jakafi patent cliff in 2028 make it prudent to hold off on investing right now. The technical indicators also do not suggest a strong entry point.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 45.592, and moving averages are converging, showing no clear trend. Key support is at 89.934, and resistance is at 94.258. The stock is trading near its pivot point of 92.096, suggesting limited short-term movement.
FDA approval of Opzelura® for vitiligo, marking a significant market opportunity.
Strong financial performance in Q4 2025 with YoY revenue growth of 27.84% and EPS growth of 50.52%.
Promising pipeline developments, including Phase 3 trials for povorcitinib in multiple indications.
Analyst downgrades citing concerns about the Jakafi patent cliff in
Lack of significant near-term catalysts as noted by analysts.
Stock trend analysis predicts a decline of -1.07% in the next day, -3.21% in the next week, and -5.62% in the next month.
In Q4 2025, Incyte reported a 27.84% YoY increase in revenue, a 48.74% YoY increase in net income, and a 50.52% YoY increase in EPS. However, gross margin slightly declined by 0.57% YoY to 91.96%.
Recent analyst ratings are mixed to negative. UBS and Jefferies lowered their price targets to $94, citing concerns about the Jakafi patent cliff. Barclays, Stifel, and Piper Sandler raised their price targets, but the upgrades are based on long-term potential rather than near-term catalysts.
